tradmap

DYAI DYADIC INTERNATIONAL INC

$0.50 -4.92%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

DYADIC INTERNATIONAL INC (DYAI) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $18 million. Shares last traded at $0.50, 68.3% below their 52-week high. Over the past year the stock is down 50.0%. Net profit margin is -200.5%, below the peer median of 5.3%. Revenue declined 11.6% year over year.

Market Cap
$18M
Shares Out
36.4M
EPS (TTM)
$-0.46
P/E Ratio
P/S Ratio
4.84
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$1.59
52-Week Low
$0.49
Volume
10,403
Avg Vol (3m)
3,960.968

Performance

1W
-20.61%
1M
-46.88%
3M
-30.27%
6M
-36.91%
YTD
-44.99%
1Y
-50.03%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
21.72
SMA (50)
$0.94
SMA (200)
$0.87
Price vs SMA50
-46.03%
Price vs SMA200
-42.32%
ATR (14)
$0.06

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$4M
Net Income
$-8M
Gross Margin
16.2%
Operating Margin
-195.1%
Net Margin
-200.5%
Return on Equity
319.3%
Return on Assets
-116.6%
Current Ratio
1.65
Debt / Equity
-3.74
Revenue Growth (YoY)
-11.6%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.11 2026-08-12
Q1 2026 $-0.05 2026-05-13
FY 2025 $-0.23 2026-03-25
Q3 2025 $-0.17 2025-11-12
Q2 2026 $-0.13 2026-08-12
Q1 2026 $-0.07 2026-05-13

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

DYAI vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
4.84 / 19.49 med
-75% discount
Net margin vs peers
-200.5% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.